Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

What Interval of Daily Pain Assessment Is Required to Reliably Diagnose Chronic Pain in Sickle Cell Disease? the Pisces Study

Wally R Smith, Donna McClish

Blood (2023) 142 (Supplement 1): 252.

https://doi.org/10.1182/blood-2023-178065

Published: 2023

Journal Articles

A Patient-Centric Approach to Sickle Cell Disease Clinical Trials: Integrating Patient Perspectives in the RISE UP Phase 2/3 Trial of Mitapivat for Informed Protocol Design and Associated Patient Community Benefit

Charles R. Jonassaint, Blaze Armon Eppinger, Dominique Friend, Golie Lorenzo Green, Mia Robinson, Teonna Woolford, DeMitrious Wyant, Janie Davis, Abdulafeez Oluyadi, Ahmar U Zaidi, Holly John, Wally R Smith

Blood (2023) 142 (Supplement 1): 2376.

https://doi.org/10.1182/blood-2023-186710

Published: 2023

Journal Articles

Incidence, Prevalence, and Disease Management Impactability of High Utilization in an Adult Sickle Cell Medical Home

Wally R Smith, Daniel Sop, Yue May Zhang, Benjamin Jaworowski, Shirley Johnson

Blood (2023) 142 (Supplement 1): 7206.

https://doi.org/10.1182/blood-2023-187621

Published: 2023

Journal Articles

Component-Specific Effects of Team Case Management on Adult Sickle Cell Utilization in Moderate to Low Utilizers

Shirley Johnson, Daniel Sop, Austin Hardy, Rachel Walls, Yue May Zhang, Benjamin Jaworowski, Wally R Smith

Blood (2023) 142 (Supplement 1): 7197.

https://doi.org/10.1182/blood-2023-187590

Published: 2023

Journal Articles

Quality of Care Among Emerging Adults with Sickle Cell Disease Using the Ascq-ME Qoc Measure: Baseline ST3P-up Study Data Results

Ifeyinwa Osunkwo, Myra Robinson, Anya Griffin, Azizi Coleman, Sharvil Desai, Padmaja Veeramreddy, Payal Desai, Charity Patterson, James Symanowski, Paulette Bryant, Jennifer Cornette, Wally R Smith, James R Eckman, Ramona Lawrence

Blood (2023) 142 (Supplement 1): 5048.

https://doi.org/10.1182/blood-2023-186835

Published: 2023

Journal Articles

Relative Influence of Biological Versus Behavioral Determinants of Utilization Among Adults with Sickle Cell Disease

Mica Ferlis, Daniel Sop, Yue May Zhang, Wally R Smith

Blood (2023) 142 (Supplement 1): 3680.

https://doi.org/10.1182/blood-2023-187483

Published: 2023

Journal Articles

Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

Miguel R Abboud, Rodolfo D Cançado, Mariane De Montalembert, Wally R Smith, Hala Rimawi, Ersi Voskaridou, Birol Guvenc, Deborah Keefe, Kai Grosch, Michele L Nassin, Jimmy Watson, Justin Yssel, Evgeniya Reshetnyak, Yvonne Dei Adomakoh

Blood (2023) 142 (Supplement 1): 272.

https://doi.org/10.1182/blood-2023-185429

Published: 2023

Journal Articles

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

Blood (2023) 142 (Supplement 1): 271.

https://doi.org/10.1182/blood-2023-187033

Published: 2023

Journal Articles

Towards an Implicit Measure of Patient Engagement in Sickle Cell Disease: Relationships between Implicit Measures of Engagement and Previous Childhood Trauma Among Adolescents and Young Adults

Haylee Hartzog, Shirley Johnson, Rachel Walls, Yue May Zhang, Daniel Sop, Wally R Smith

Blood (2023) 142 (Supplement 1): 7319.

https://doi.org/10.1182/blood-2023-187552

Published: 2023

Journal Articles

Inpatient Reliance Ratio Versus Emergency Department Reliance Ratio in a Sickle Cell Disease Medical Home

Daniel M Sop, Yue May Zhang, Shirley Johnson, Benjamin Jaworowski, Wally R Smith

Blood (2022) 140 (Supplement 1): 7881–7882.

https://doi.org/10.1182/blood-2022-170137

Published: 2022

Journal Articles

Sickle Cell Disease May Qualify As an Ambulatory Care Sensitive Condition

Wally R Smith, Yue May Zhang, Shirley Johnson, Daniel M Sop

Blood (2022) 140 (Supplement 1): 7862–7863.

https://doi.org/10.1182/blood-2022-169474

Published: 2022

Journal Articles

Expansion of Content in the Phenx Toolkit for Sickle Cell Disease Pain

Stephanie H Guarino, Mark D Nelms, David Williams, Amanda M. Brandow, C. Patrick Carroll, Nitya Bakshi, Claudia M Campbell, Deepika S. Darbari, Martha Kenney, Wally R Smith, Jennifer Stinson, William Zempsky, Wayne Huggins, Deborah Maiese, Tabitha Hendershot, Carol Hamilton

Blood (2022) 140 (Supplement 1): 8302–8304.

https://doi.org/10.1182/blood-2022-169277

Published: 2022

Journal Articles

Screening for Adverse Childhood Experiences (ACEs) As a Way to Predict Overdose Risk in Adult Sickle Cell Patients

Rachel Walls, Daniel M Sop, Yue May Zhang, Benjamin Jaworowski, Shirley Johnson, Wally R Smith

Blood (2022) 140 (Supplement 1): 13039–13040.

https://doi.org/10.1182/blood-2022-169541

Published: 2022

Journal Articles

Oxycodone Produces Antinociception, but Worsens Functional Behaviors, in Humanized Sickle Cell Disease Mice

Kennedy N Goldsborough, Molly Sonenklar, Kalpna Gupta, M Imad Damaj, Wally R Smith, Joyce Lloyd, Aron Lichtman

Blood (2022) 140 (Supplement 1): 5448–5449.

https://doi.org/10.1182/blood-2022-162675

Published: 2022

Journal Articles

Intensive Case Management in an Adult Sickle Cell Medical Home: Annual Effects on Utilization Efficiency Using Community Health Workers

Shirley Johnson, Daniel M Sop, Yue May Zhang, Benjamin Jaworowski, Wally R Smith

Blood (2022) 140 (Supplement 1): 1625–1626.

https://doi.org/10.1182/blood-2022-169193

Published: 2022

Journal Articles

Monoacylglycerol Lipase Inhibition: A Strategy to Treat Chronic Pain in a Humanized Sickle Cell Mouse Model

Kennedy N Goldsborough, Karan Mucchala, Kalpna Gupta, Joyce Lloyd, Hamid Akbarali, Wally R Smith, Aron Lichtman

Blood (2021) 138 (Supplement 1): 956.

https://doi.org/10.1182/blood-2021-153529

Published: 2021

Journal Articles

COVID Symptoms and COVID Anxiety in Sickle Cell Disease

Wally R Smith, MD, Benjamin Jaworowski, BS, Shirley Johnson, BA, LSW, Thokozeni Lipato, MD, Daniel M Sop, BS,MS

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-143054

Published: 2020

Journal Articles

Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis

Carlton D. Dampier, MD, Marilyn J. Telen, MD, Ted Wun, MD, Wally R Smith, MD, R. Clark Brown, MD PhD, Payal Desai, MD, Fuad A El Rassi, MD, Julie Kanter, MD, Beng R. Fuh, MD, Yves D. Pastore, MD, Jennifer A. Rothman, MD, James G. Taylor, MD, David Readett, BM, BS, MRCP, Jay N Lozier, MDPhD, John L. Magnani, PhD, Helen M Thackray, MD, Kathryn L. Hassell, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-134803

Published: 2020

Journal Articles

The Effect of Crizanlizumab on the Number of Days Requiring Opioid Use for Management of Pain Associated with Vaso-Occlusive Crises in Patients with Sickle Cell Disease: Results from the Sustain Trial

Wally R Smith, MD, Kenneth I. Ataga, MD, Santosh L. Saraf, MD, Olufolake A. Adisa, MDMSc, Miranda Bailey, Nicholas Ramscar, MBBS, Ashley Bonner, PhD, Stephen Brown, PhD, Laura Pastor, MSc

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140428

Published: 2020

Journal Articles

Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial

Wally R Smith, MD, Jane S. Hankins, MD MS, Miguel R Abboud, MD, Ze Cong, PhD, Jonathan Sorof, MD, Sarah Gray, PhD, Carolyn Hoppe, MD, Paul Telfer, DM, FRCP

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-137121

Published: 2020

NARROW

What Interval of Daily Pain Assessment Is Required to Reliably Diagnose Chronic Pain in Sickle Cell Disease? the Pisces Study

A Patient-Centric Approach to Sickle Cell Disease Clinical Trials: Integrating Patient Perspectives in the RISE UP Phase 2/3 Trial of Mitapivat for Informed Protocol Design and Associated Patient Community Benefit

Incidence, Prevalence, and Disease Management Impactability of High Utilization in an Adult Sickle Cell Medical Home

Component-Specific Effects of Team Case Management on Adult Sickle Cell Utilization in Moderate to Low Utilizers

Quality of Care Among Emerging Adults with Sickle Cell Disease Using the Ascq-ME Qoc Measure: Baseline ST3P-up Study Data Results

Relative Influence of Biological Versus Behavioral Determinants of Utilization Among Adults with Sickle Cell Disease

Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

Towards an Implicit Measure of Patient Engagement in Sickle Cell Disease: Relationships between Implicit Measures of Engagement and Previous Childhood Trauma Among Adolescents and Young Adults

Inpatient Reliance Ratio Versus Emergency Department Reliance Ratio in a Sickle Cell Disease Medical Home

Sickle Cell Disease May Qualify As an Ambulatory Care Sensitive Condition

Expansion of Content in the Phenx Toolkit for Sickle Cell Disease Pain

Screening for Adverse Childhood Experiences (ACEs) As a Way to Predict Overdose Risk in Adult Sickle Cell Patients

Oxycodone Produces Antinociception, but Worsens Functional Behaviors, in Humanized Sickle Cell Disease Mice

Intensive Case Management in an Adult Sickle Cell Medical Home: Annual Effects on Utilization Efficiency Using Community Health Workers

Monoacylglycerol Lipase Inhibition: A Strategy to Treat Chronic Pain in a Humanized Sickle Cell Mouse Model

COVID Symptoms and COVID Anxiety in Sickle Cell Disease

Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis

The Effect of Crizanlizumab on the Number of Days Requiring Opioid Use for Management of Pain Associated with Vaso-Occlusive Crises in Patients with Sickle Cell Disease: Results from the Sustain Trial

Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only